OBJECTIVE: The National Heart, Lung, and Blood Institute convened an interdisciplinary working group of experts to develop recommendations for the assessment and treatment of depression in patients with coronary heart disease (CHD). METHOD: Consensus of experts. RESULTS: Our current recommendations are that the Beck Depression Inventory-I be employed for epidemiological studies of depression and CHD, that the Patient Health Questionnaire 2-item version be employed for screening for trial eligibility, that the Depression Interview and Structured Hamilton (DISH) be employed for diagnostic ascertainment for trial inclusion, and that the Hamilton rating scale, which is part of the DISH, be employed for both depression symptom reduction and the remission criterion in any trial. We further recommend that a randomized controlled trial be undertaken to determine whether selective serotonin reuptake inhibitors, psychotherapy, or combined treatment can reduce the risk of CHD events and mortality associated with depression in CHD patients. CONCLUSIONS: This report summarizes the recommendations made by the working group and discusses the rationale for each recommendation, the strengths and weaknesses of alternative approaches to assessment and treatment, and the implications for future research in this area.
RCT Entities:
OBJECTIVE: The National Heart, Lung, and Blood Institute convened an interdisciplinary working group of experts to develop recommendations for the assessment and treatment of depression in patients with coronary heart disease (CHD). METHOD: Consensus of experts. RESULTS: Our current recommendations are that the Beck Depression Inventory-I be employed for epidemiological studies of depression and CHD, that the Patient Health Questionnaire 2-item version be employed for screening for trial eligibility, that the Depression Interview and Structured Hamilton (DISH) be employed for diagnostic ascertainment for trial inclusion, and that the Hamilton rating scale, which is part of the DISH, be employed for both depression symptom reduction and the remission criterion in any trial. We further recommend that a randomized controlled trial be undertaken to determine whether selective serotonin reuptake inhibitors, psychotherapy, or combined treatment can reduce the risk of CHD events and mortality associated with depression in CHD patients. CONCLUSIONS: This report summarizes the recommendations made by the working group and discusses the rationale for each recommendation, the strengths and weaknesses of alternative approaches to assessment and treatment, and the implications for future research in this area.
Authors: William Whang; Daichi Shimbo; Ian M Kronish; W Lane Duvall; Howard Julien; Padmini Iyer; Matthew M Burg; Karina W Davidson Journal: Am J Cardiol Date: 2010-10-15 Impact factor: 2.778
Authors: Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy Journal: CNS Drugs Date: 2010-09 Impact factor: 5.749
Authors: William Whang; Matthew M Burg; Robert M Carney; Kenneth E Freedland; J Thomas Bigger; Diane Catellier; Susan Czajkowski; Nancy Frasure-Smith; Donald C Haas; Allan S Jaffe; Francois Lespérance; Vivian Medina; Joan Duer-Hefele; Gabrielle A Osorio; Faith Parsons; Peter A Shapiro; David S Sheps; Viola Vaccarino; Karina W Davidson Journal: Contemp Clin Trials Date: 2012-05-25 Impact factor: 2.226
Authors: Jeanne M McCaffery; Qing Ling Duan; Nancy Frasure-Smith; Amina Barhdadi; Francois Lespérance; Pierre Théroux; Guy A Rouleau; Marie-Pierre Dubé Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-04-05 Impact factor: 3.568
Authors: Bruce L Rollman; Bea Herbeck Belnap; Michelle S LeMenager; Sati Mazumdar; Herbert C Schulberg; Charles F Reynolds Journal: Psychosom Med Date: 2009-02-02 Impact factor: 4.312